2,800 Amgen Inc. $AMGN Shares Purchased by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.8% in the third quarter, HoldingsChannel.com reports. The firm owned 159,819 shares of the medical research company’s stock after buying an additional 2,800 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Amgen were worth $67,365,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in AMGN. State Street Corp raised its holdings in Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares during the last quarter. Bank of America Corp DE bought a new stake in Amgen in the 2nd quarter worth $1,831,903,000. Wellington Management Group LLP grew its holdings in Amgen by 1,102.7% in the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after acquiring an additional 2,514,254 shares during the last quarter. BlackRock Inc. increased its position in shares of Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares during the period. Finally, Corient Private Wealth LP purchased a new position in shares of Amgen in the second quarter valued at about $187,401,000. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 1.4%

Shares of AMGN opened at $407.44 on Friday. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm’s 50-day moving average price is $412.35 and its 200-day moving average price is $371.88. The firm has a market capitalization of $220.27 billion, a price-to-earnings ratio of 25.32, a PEG ratio of 2.98 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the firm earned $6.02 earnings per share. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. Amgen’s dividend payout ratio is 62.65%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen is advancing a Phase 3 head-to-head trial of its monthly diabetes treatment, MariTide, against semaglutide-based therapy. A successful study could strengthen Amgen’s position in the highly competitive GLP-1 and obesity-treatment markets and provide a significant future growth opportunity. Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
• Positive Sentiment: Amgen’s recently announced Sjögren’s syndrome trial results appear to have supported investor sentiment, contributing to gains in the prior session. Further details on efficacy and regulatory plans will determine the longer-term impact. Amgen Announces Sjögren’s Trial Results
• Neutral Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing for AI-driven genetic testing. The investment may give Amgen access to molecular data useful for precision-medicine research, but it is unlikely to materially affect near-term earnings. Amgen Backs $30 Million Series A Round
• Neutral Sentiment: AMGN advanced about 2.6% in the prior session while the broader market declined, suggesting recent relative strength; however, this move may also have increased the potential for profit-taking. Amgen Advances While Market Declines
• Negative Sentiment: Morgan Stanley cut its price target to $359 from $362 and maintained an Equal Weight rating. Truist raised its target to $380 but kept a Hold rating. Both targets imply downside from Amgen’s recent price, reinforcing valuation concerns. Morgan Stanley Adjusts Price Target on Amgen

Analyst Ratings Changes

AMGN has been the subject of a number of analyst reports. Guggenheim increased their target price on shares of Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a report on Monday, August 10th. Truist Financial boosted their price target on Amgen from $362.00 to $380.00 and gave the company a “hold” rating in a report on Wednesday. Sanford C. Bernstein upped their price target on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Scotiabank increased their price objective on Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. Finally, Weiss Ratings upgraded Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $388.29.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 in the last three months. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.